HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating for Summit Therapeutics (NASDAQ:SMMT) and maintained a price target of $45.
October 04, 2024 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Summit Therapeutics, maintaining a $45 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $45 price target by a reputable analyst suggests positive sentiment and confidence in Summit Therapeutics' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100